Long-term use of secukinumab for juvenile psoriatic arthritis and enthesitis-related arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study looks at how well secukinumab, a biologic medicine, works over the long term for children and teenagers with two types of juvenile arthritis: psoriatic arthritis (which also involves skin psoriasis) and enthesitis-related arthritis (which causes pain where tendons meet bones). It uses data from a German registry to see if the treatment is effective and safe in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 17 years old.
- You must have a diagnosis of juvenile psoriatic arthritis or enthesitis-related arthritis as defined by standard criteria.
- You must have started secukinumab after it was approved in Germany and as per its label.
- You must have consent from your parent or legal guardian, and if you are 11 or older, you must also agree to participate.
- You cannot be taking other biologic medicines or JAK inhibitors at the same time as secukinumab.
- You cannot be enrolled in any other interventional clinical trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
This study looks at how different ways of taking secukinumab (Cosentyx) over the long term affect skin clearance in people with moderate-to-severe psoriasis. It tries to find which dosing schedule keeps skin clear best over time.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study tests a medicine called secukinumab, given as an injection, to see if it helps people with severe erythrodermic psoriasis — a type of psoriasis that covers most of the body with redness and scaling. The goal is to improve skin symptoms and quality of life.
Hear when a new Enthesitis-related Arthritis (ERA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.